A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who do not have a known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 or SARS-CoV-2 infection.
Epistemonikos ID: 84549c94cfaf0103136ac2c70205f8a705cd1215
First added on: May 28, 2021